Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that the upcoming Annual General Meeting will be held on June 6, 2025, in Paris, France.

Read more at globenewswire.com